Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

This study has been completed.
Sponsor:
Information provided by:
Mylan Bertek Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00142545
First received: August 31, 2005
Last updated: NA
Last verified: July 2005
History: No changes posted
  Purpose

The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.


Condition Intervention Phase
Parkinson Disease
Drug: apomorphine HCl injection
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease

Resource links provided by NLM:


Further study details as provided by Mylan Bertek Pharmaceuticals:

Primary Outcome Measures:
  • adverse events (AE)s
  • clinical laboratory tests
  • vital signs
  • electrocardiogram
  • orthostatic monitoring

Secondary Outcome Measures:
  • • Hoehn and Yahr Score
  • • UPDRS score - Motor Exam (Section III)
  • • UPDRS score - Total
  • • UPDRS score - Non-Motor Exam (Subtotal of Sections I, II, and IV)
  • • UPDRS score – Complications of Therapy (Section IV)
  • • Number of Off episodes based diary entries
  • • Duration of Off episodes based on diary entries
  • • Number of daily injections based on diary entries
  • • Length of time from injection to On based on diary entries

Estimated Enrollment: 800
Study Start Date: July 1999
Estimated Study Completion Date: July 2005
Detailed Description:

The primary objective of APO401 was to gain additional safety data in the outpatient use of apomorphine. APO401 provided an opportunity for all patients who had participated in a Mylan-sponsored placebo controlled trial of apomorphine to receive apomorphine therapy as ambulatory outpatients. Patients other than those enrolled in a Mylan-sponsored study were allowed to participate. Additional data regarding the safety and effectiveness of outpatient use of subcutaneous apomorphine were derived from this experience.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prior participation in a MYLAN sponsored study of subcutaneous apomorphine administration for the treatment of Off episodes due to end-of-dose motor deterioration ("Wearing-Off" effect) or sudden loss of mobility at seemingly random intervals ("On-Off" effect). With prior approval from MYLAN, patients other than those enrolled in a MYLAN sponsored study were allowed to participate. Following approval of Amendment 01, patients who met all other criteria for inclusion, regardless of previous participation in an apomorphine study, were allowed to participate.
  • Age: Adults of any age > 18.
  • Sex: Men and non-pregnant, non-lactating women.
  • Women of childbearing potential must have had a negative serum (Beta HCG) pregnancy test within 14 days of the study start.
  • Women of childbearing potential must have used an acceptable form of contraception.
  • Patients with a clinical diagnosis of idiopathic Parkinson’s Disease, i.e., not induced by drugs or caused by other diseases.
  • Patients classified as stage II - V of the Hoehn and Yahr scale for staging the severity of Parkinson's Disease.
  • Patients with refractory motor fluctuations of any frequency or duration. These include but are not necessarily limited to patients with the following symptoms:

    • Immobility resulting from regular dose failures.
    • Severe Off period discomfort.
    • Nocturnal/early morning dystonias.
    • Voiding dysfunctions.
    • Swallowing difficulties associated with Off periods.
    • Off period visual hallucinations.
    • Severe biphasic dyskinesia.
  • The patient (or a caregiver) had to be able to recognize an Off state, and be sufficiently motivated to learn how to use the apomorphine injection to control these periods.
  • The patient (or a caregiver) had to be able to maintain On-Off diaries.
  • Unless otherwise specified, enrolled patients must be on an optimally maximized oral therapy regimen. Optimized oral anti-PD medication included: levodopa/carbidopa in either immediate or delayed release forms, plus at least one direct acting oral dopamine agonist for at least 30 days prior to enrollment into study.

Exclusion Criteria:

  • Patients under medical therapy for clinically significant psychoses or dementia not related to ingestion of anti-PD medications. (Patients with hallucinations or other central adverse reactions associated solely with anti-PD medications were not excluded.)
  • Patients with a history of drug or alcohol dependency within one year prior to study enrollment.
  • Patients with unstable and clinically significant disease of cardiovascular (including orthostatic hypotension), hematologic (including Coombs’ positive hemolytic anemia), hepatic, renal, metabolic, respiratory, gastrointestinal or endocrinological systems or neoplasm within the three months before the start of the study.
  • Patients with a history of true allergy to morphine or its derivatives (including apomorphine), sulfur, sulfur containing medication, sulfites, sulfates, Tigan(R) (trimethobenzamide).
  • Patients treated with experimental agents (other than apomorphine intermittent subcutaneous injections) within 30 days before study entry. Patients with participation in Bertek-sponsored study APO202 were excluded from participation in this study.
  • Patients whose apomorphine regimen was characterized by administration methods other than intermittent subcutaneous injection.
  • Patients who could not or would not sign an Informed Consent form.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00142545

Locations
United States, West Virginia
Mylan Pharmaceuticals
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
Mylan Bertek Pharmaceuticals
Investigators
Study Director: Will Sullivan Mylan Bertek Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00142545     History of Changes
Other Study ID Numbers: APO401
Study First Received: August 31, 2005
Last Updated: August 31, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Apomorphine
Emetics
Physiological Effects of Drugs
Pharmacologic Actions
Autonomic Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 30, 2014